
==== Front
BMC Public Health
BMC Public Health
BMC Public Health
1471-2458
BioMed Central London

19944
10.1186/s12889-024-19944-2
Research
Trends of older gastric cancer incidence, mortality, and survival in the highest gastric cancer risk area in China: 2010–2019 and prediction to 2024
Niu Penghui 1
Zhang Fan 2
Ma Deyuan 3
Zhou Xiadong 4
Zhu Yitong 5
Luan Xiaoyi 1
Zhao Lulu 1
Wang Wanqing 1
Zhang Xiaojie 6
Han Xue 1
He Mingyan 119273873@qq.com

4
Guan Quanlin guanquanlin@163.com

3
Li Yumin liym@lzu.edu.cn

2
Liu Yuqin liuyq970930@126.com

4
Chen Yingtai yingtaichen@126.com

1
1 https://ror.org/02drdmm93 grid.506261.6 0000 0001 0706 7839 National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 https://ror.org/02erhaz63 grid.411294.b 0000 0004 1798 9345 Lanzhou University Second Hospital, Lanzhou, China
3 https://ror.org/05d2xpa49 grid.412643.6 The First Hospital of Lanzhou University, Lanzhou, China
4 grid.461867.a 0000 0004 1765 2646 Gansu Provincial Cancer Hospital, Lanzhou, China
5 https://ror.org/02drdmm93 grid.506261.6 0000 0001 0706 7839 Peking Union Medical College School of Population Medicine and Public Health, Beijing, China
6 https://ror.org/037cjxp13 grid.415954.8 0000 0004 1771 3349 Gastrointestinal Surgery Department, China-Japan Friendship Hospital, Beijing, China
9 9 2024
9 9 2024
2024
24 244924 12 2023
29 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Gastric cancer is a major health problem worldwide, with a high incidence among older adults. Given the aging overall population, it was crucial to understand the current burden and prospective trend of older gastric cancer. This study aimed to analyze the temporal trends of the incidence, mortality, and survival of older gastric cancer in the highest gastric cancer risk area in China from 2010 to 2019, and to predict the future burden of older gastric cancer up to 2024.

Methods

The study was conducted in Gansu province, an area characterized by the highest gastric cancer incidence and mortality in China. The registration data of gastric cancer incidence and mortality from 2010 to 2019 were pooled from registries in the Gansu Cancer Registration System, while survival data were collected from the First Hospital of Lanzhou University, Lanzhou University Second Hospital, and Gansu Cancer Hospital. Chinese standard population in 2000 and the Segi’s world standard population were applied to calculate the age-standardized rate. Joinpoint regression was used to analyze the average annual percentage change (AAPC) in cancer incidence and mortality. Autoregressive Integrated Moving Average (ARIMA) models were employed to generate forecasts for incidence and mortality from 2020 to 2024.

Results

Based on registry data from 2010 to 2019, the incidence and mortality rates of gastric cancer among older adults remained stable. The incidence rates declined from 439.65 per 100,000 in 2010 to 330.40 per 100,000 in 2019, with an AAPC of -2.59% (95% confidence interval[CI], -5.14 to 0.04, P = 0.06). Similarly, the mortality rate changed from 366.98 per 100,000 in 2010 to 262.03 per 100,000 in 2019, with an AAPC of -2.55% (95% CI, -8.77–4.08%, P = 0.44). In the hospital-based cohort, the decline in survival rates was reported among older patients with gastric cancer in the highest gastric cancer risk area in China, with the 3-year overall survival (OS) decreasing from 58.5% (95% CI, 53.5–63.2%) in 2010 to 34.4% (95%CI, 32.1–36.7%) in 2019, and the 3-year progression-free survival (PFS) decreasing from 51.3% (95%CI, 47.5–55.1%) in 2010 to 34.2% (95%CI, 32.0–36.3%) in 2019, respectively. Moreover, forecasts generated by ARIMA models revealed a significant decline in the incidence and mortality of older gastric cancer in China from 2020 to 2024. Specifically, the incidence rate of older gastric cancer was expected to decrease from 317.94 per 100,000 population in 2020 to 205.59 per 100,000 population in 2024, while the anticipated mortality rate was estimated to decrease from 222.52 per 100,000 population in 2020 to 186.22 per 100,000 population in 2024.

Conclusion

From 2010 to 2019, the incidence and mortality of older gastric cancer remained stable in the highest gastric cancer risk area in China, while the survival rates showed a decline. Based on the ARIMA models, it was anticipated that there might be a continued decline in older gastric cancer incidence and mortality in the highest-risk area in China over the next five years.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12889-024-19944-2.

Keywords

Gastric cancer
Older adults
Incidence
Mortality
Survival
ARIMA models
Beijing Hope Run Special Fund of Cancer Foundation of ChinaGrant No. LC2022A29 2023 Scientific Research Project of Chronic Diseases Control and Health EducationNo.BJMB0012023024005 http://dx.doi.org/10.13039/501100005090 Beijing Nova Program No.20220484200 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

The worldwide burden of cancer was rapidly increasing as people lived longer and reached older ages [1, 2]. Among the five most prevalent cancers worldwide, gastric cancer ranks fifth, with over 58% of newly diagnosed cases occurring in individuals aged 65 years and older [3]. Notably, China bears a significant burden of gastric cancer, accounting for 42% of global cases [4].

Gansu was the province with the highest incidence and mortality of gastric cancer in China, with the incidence of 79.04 per 100,000 and the mortality of 60.33 per 100,000 in 2016 [5]. There has been an increase in the number of people aged 65 years and older in Gansu province over the past few years, with an increase from 8.23% in 2010 to 13.44% in 2022 [6]. Li et al. [7] reported that the incidence and mortality rates of gastric cancer have increased from 2003 to 2012 in Wuwei, Gansu province. However, the comprehensive analysis of incidence and mortality of gastric cancer among older adults in Gansu province was still lacking. Nevertheless, the survival trends of older patients with gastric cancer in the highest gastric cancer risk area in China remained to be elucidated.

Based on the registration data and hospital-based data, this study was conducted to examine trends of the incidence, mortality, and survival of older gastric cancer in the highest gastric cancer risk area in China from 2010 to 2019, as well as to predict the future cancer burden up to 2024, which may provide valuable information for the adjustment of health policies and optimization of medical resources.

Methods

Study population and data source

In this study, both cancer registration data and hospital-based data in the area with the highest cancer risk in China were used to evaluate the older gastric cancer burden and temporal trends from 2010 to 2019. The incidence and mortality rates of older gastric cancer were pooled from registries in the Gansu Cancer Registration System. Until now, 23 cancer registration sites in Gansu Province reported the 2019 cancer registration data, which covering 36.96% of the province’s population. Gastric cancer was identified by the International Classification of Diseases for Oncology, third edition (ICD-O-3)-tomography (ICD-O-3-T) codes of C16.0-C16.9. Population data were obtained from the data on the total number of residents, gender and age group composition collected annually by local public security departments and statistical departments. Furthermore, survival data of older gastric cancer patients were collected from the First Hospital of Lanzhou University, Lanzhou University Second Hospital, and Gansu Cancer Hospital. The endpoints under consideration in this study were Progress-Free Survival (PFS) and Overall Survival (OS). PFS was delineated as the duration from the date of diagnosis until the occurrence of recurrence, metastasis, or death. Conversely, OS was defined as the time interval from the initiation of diagnosis to the event of death under any circumstance. Enrollment criteria included individuals aged 65 years and older, born and resided in Gansu province, and without a previous cancer diagnosis, except for gastric cancer.

Quality control

The data quality of Gansu Cancer Registry Center was assessed according to the criteria set out in the Guidebook for Cancer Registration in China [8] and the International Center for Research on Cancer (IARC)/The relevant requirements of the International Association for Cancer Registries (IACR) on registration quality [9, 10]. The reliability, completeness, and validity of the data were evaluated according to the main indicators such as the proportion of pathological diagnoses (MV%), the proportion of only death certificates (DCO%), and the death/morbidity ratio (M/I). Finally, the MV%, DCO%, and M/I of the aggregated cancer registry regions included in the analysis were 60.31%, 2.13%, and 0.56, respectively. MSFoxPro, MS-Excel, SAS 9.4, and IARC/IACR’s IARC crgTools software were used [11] to review and evaluate registration and hospital data.

Statistical analysis

The data of each cancer registration site that met the quality control standards of cancer registration were merged and analyzed. The incidence and mortality of older gastric cancer in the highest gastric cancer risk area of China were stratified by area (urban or rural) and gender. According to the National Cancer Center, cities above prefecture level are considered urban areas while counties or county-level cities are considered rural areas. Chinese standard population in 2000 and the Segi’s world standard population were respectively used to calculate the Chinese age-standardized incidence/mortality rate (ASIRC/ASMRC) and the world age-standardized mortality rate (ASIRW/ASMRW). The average annual percent change (AAPC) for the period of 2010–2019 was calculated using the Joinpoint Regression Program to assess changing trends in the incidence and mortality of older gastric cancer. Survival analyses were calculated with the log-rank regression. The Chi-squared test was performed to compare the difference between registration data and hospital-based data. The Autoregressive Integrated Moving Average (ARIMA) model was a useful tool for assessing the impact of large-scale interventions, and it’ s objective was to enhance the predictive accuracy over more rudimentary regression models by characterizing the auto-correlation present within the data, identifying trends, and subsequently integrating this information into the forecast. By incorporating the onset and death time of each older gastric cancer case, while considering variables such as age, gender, geographical location, and seasonal patterns, ARIMA models were employed to generate forecasts for incidence and mortality of older gastric cancer from 2020 to 2024. The stability and reliability of the model were assessed using the mean square error (MSE). The above analysis was conducted using SAS software (Version 9.4), Python software (Version 3.8.1), and Joinpoint Trend Analysis Software (Version 4.9.1.0).

Results

Trends in the incidence of older gastric cancer from 2010 to 2019

Table 1; Fig. 1 set out the estimated number of new older gastric cancer cases and the incidence of older gastric cancer during 2010–2019. Overall, the incidence, ASIRC, ASIRW of older gastric cancer in the highest gastric cancer risk area in China were observed to decline from in 439.65 per 100,000, 427.39 per 100,000, 422.18 per 100,000 in 2010 to 330.40 per 100,000, 334.38 per 100,000, and 326.27 per 100,000 in 2019, respectively. However, the results of AAPCs showed no statistic difference for the changing trends of incidence (AAPCs of − 2.59% (95% CI: -5.14 to 0.04%, P = 0.06) in the crude incidence, AAPCs of − 2.32% (95% CI: -5.02 to 0.46%, P = 0.10) in ASIRC, AAPCs of − 2.56% (95% CI: -5.23 to 0.18, P = 0.07) in ASIRW, respectively.). After stratified by sex and area, the incidence of older male gastric cancer was higher than these in females (male to female ratio ranging from 2.90 to 3.73). The incidence of older gastric cancer was also higher in urban areas than rural areas (urban to rural ratio ranging from 1.01 to 1.72), except the incidence in 2012 (urban to rural ratio: 0.75). Moreover, except the crude incidence trends of older female patients with gastric cancer (AAPCs of − 3.12% (95% CI: -6.00% to -0.15%, P = 0.04), no statistical significance were observed in other subgroups of older gastric cancer (AAPCs of − 3.64% (95% CI: -8.02–0.94%), P = 0.12 in males, AAPCs of − 2.58% (95% CI: -5.77–0.72%), P = 0.12 in urban areas, and AAPCs of − 3.15% (95% CI: -8.68–2.72%), P = 0.25 in rural areas, respectively.).

Table 1 Estimated numbers of new older gastric cancer cases and the incidence in the highest gastric cancer risk area in China, 2010 to 2019 (per 100,000 population)

	Total		Male		Female		Urban		Rural	
Incidence	ASIRC	ASIRW		Incidence	ASIRC	ASIRW		Incidence	ASIRC	ASIRW		Incidence	ASIRC	ASIRW		Incidence	ASIRW	ASIRC	
	2010	439.65	427.39	422.18		656.25	637.77	629.50		220.67	214.67	212.49		475.47	459.89	454.06		324.56	320.40	317.52	
	2011	427.30	420.39	423.63		629.34	622.13	625.02		214.18	208.66	212.01		448.09	437.68	441.33		361.63	358.85	360.82	
	2012	463.18	467.18	469.40		692.39	687.10	686.27		238.57	252.30	257.54		435.57	432.76	433.56		580.19	615.36	614.38	
	2013	469.55	461.41	464.69		718.72	707.67	715.50		226.33	219.16	217.69		503.74	494.24	498.61		356.63	356.99	356.09	
	2014	492.53	485.96	484.00		766.37	755.17	754.17		224.36	222.05	218.44		503.68	492.78	493.17		442.19	467.13	452.09	
	2015	487.73	483.15	484.65		758.72	752.69	749.77		222.97	220.48	225.50		537.98	531.67	537.42		312.39	318.59	306.46	
	2016	430.74	423.75	421.17		681.32	672.24	667.78		189.83	185.87	184.16		470.30	462.41	463.64		284.06	291.29	274.23	
	2017	447.79	445.83	440.67		714.52	711.81	702.28		191.45	190.85	188.82		468.17	464.33	460.85		370.35	394.47	381.88	
	2018	374.40	374.18	367.41		565.98	566.58	560.34		189.62	189.41	181.47		398.63	398.96	393.74		272.45	282.18	269.46	
	2019	330.40	334.38	326.27		513.25	517.61	505.50		157.87	161.61	157.18		330.91	334.72	327.73		327.48	354.37	335.05	
	AAPC (%)	-2.59	-2.32	-2.56		-3.64	-3.34	-2.44		-3.12	-2.17	-2.44		-2.58	-2.24	-2.42		-3.15	-2.77	-3.29	
	95% CI (%)	(-5.14 to 0.04)	(-5.02 to 0.46)	(-5.23 to 0.18)		(-8.02 to 0.94)	(-7.58 to 1.10)	(-5.81 to 1.05)		(-6.00 to -0.15)	(-6.15 to 1.97)	(-6.78 to 2.10)		(-5.77 to 0.72)	(-5.25 to 0.87)	(-5.27 to 0.53)		(-8.68 to 2.72)	(-8.78 to 3.63)	(-9.40 to 3.24)	
	P	0.06	0.10	0.07		0.12	0.14	0.17		0.04	0.30	0.29		0.12	0.16	0.11		0.25	0.34	0.27	
ASIRC, age-standardized incidence rate by Chinese standard population; ASIRW, age-standardized incidence rate by World Segi’s standard population; AAPC: average annual percentage change

Fig. 1 Time-trends of incidence for the older gastric cancer cases in the highest gastric cancer risk area in China, 2010 to 2019. A: the incidence of older gastric cancer; B: ASIRC of older gastric cancer; C: ASIRW of older gastric cancer; D: the incidence of male older gastric cancer; E: ASIRC of male older gastric cancer; F: ASIRW of male older gastric cancer; G: the incidence of female older gastric cancer; H: ASIRC of female older gastric cancer; I: ASIRW of female older gastric cancer

Trends in the mortality of older gastric cancer from 2010 to 2019

As shown in Table 2; Fig. 2, a declining trend was observed in the mortality, ASMRC, and ASMRW of older individuals with gastric cancer in the region of highest prevalence in China from 2010 to 2019 (the mortality 366.98 per 100,000 in 2010 to 262.03 per 100,000 in 2019, ASMRC 342.28 per 100,000 in 2010 to 266.53 per 100,000 in 2019, and ASMRW 330.17 per 100,000 in 2010 to 253.78 per 100,000 in 2019, respectively.), despite the absence of statistically significant differences (AAPCs of − 2.55% (95% CI: −8.77–4.08%, P = 0.44) in the crude mortality, AAPCs of − 2.52% (95% CI: −9.34–4.82%, P = 0.49) in ASMRC, AAPCs of − 2.76% (95% CI: −8.91–3.81%, P = 0.40) in ASMRW). After stratified by sex and area, the mortality of older male gastric cancer was higher than these in females (male to female ratio ranging from 2.04 to 3.85). Moreover, the mortality of older gastric cancer was also higher in urban areas than rural areas (urban to rural ratio ranging from 1.05 to 2.43), except the incidence in 2012 (urban to rural ratio: 0.97). In addition, there were no significant mortality trends in all subgroups of older gastric cancer, with AAPCs of − 4.93% (95%CI:-11.62 to 2.26, P = 0.17) in males, AAPCs of − 3.05% (95%CI:-8.82 to 3.08, P = 0.28) in females, AAPCs of − 2.86% (95%CI:-9.23 to 3.95, P = 0.40) in urban areas, and AAPCs of − 1.45% (95%CI:-6.51 to 3.89, P = 0.54) in rural areas, respectively.

Table 2 Estimated numbers of older gastric cancer deaths and the mortality in the highest gastric cancer risk area in China, 2010 to 2019 (per 100,000 population)

	Total		Male		Female		Urban		Rural	
Mortality	ASMRC	ASMRW		Mortality	ASMRC	ASMRM		Mortality	ASMRC	ASMRW		Mortality	ASMRC	ASMRW		Mortality	ASMRC	ASMRW	
	2010	366.98	342.28	330.17		491.46	505.52	489.80		241.13	241.29	233.13		399.24	408.65	395.82		263.32	268.90	259.21	
	2011	321.68	303.39	302.25		502.93	501.80	497.04		130.50	128.92	131.22		329.03	323.85	322.27		298.49	304.23	303.96	
	2012	430.44	397.15	384.52		643.14	652.32	630.95		222.02	236.76	232.45		427.82	432.70	415.75		441.53	475.41	475.38	
	2013	420.82	378.69	367.86		652.10	660.79	644.27		195.07	194.07	188.13		467.47	474.53	464.45		266.79	271.22	262.99	
	2014	395.74	345.76	342.79		624.35	614.90	609.57		171.88	170.84	169.52		413.80	405.47	406.87		314.28	336.17	312.23	
	2015	494.33	466.94	436.38		727.15	755.33	702.12		266.86	274.34	264.82		568.86	586.52	552.48		234.29	239.90	230.51	
	2016	384.14	340.89	340.33		611.84	612.28	609.76		165.22	165.94	166.38		417.20	415.60	420.34		261.56	281.55	260.10	
	2017	426.75	385.89	367.17		652.49	669.10	640.86		209.79	212.35	201.82		446.76	451.67	428.60		350.71	373.87	372.30	
	2018	298.20	265.63	256.41		429.40	431.75	419.02		171.65	173.70	167.47		301.17	302.87	296.41		285.68	308.19	282.90	
	2019	262.03	266.53	253.78		403.60	409.40	390.51		128.44	131.89	124.85		267.42	272.28	259.06		230.80	248.16	235.52	
	AAPC (%)	-2.55	-2.52	-2.76		-4.93	-4.89	-5.12		-3.05	-2.98	-3.32		-2.86	-2.79	-3.00		-1.45	-1.16	-1.63	
	95% CI (%)	(-8.77 to 4.08)	(-9.34 to 4.82)	(-8.91 to 3.81)		(-11.62 to 2.26)	(-12.41 to 3.27)	(-11.28 to 1.46)		(-8.82 to 3.08)	(-8.96 to 3.39)	(-9.07 to 2.78)		(-9.23 to 3.95)	(-9.72 to 4.71)	(-9.02 to 3.42)		(-6.51 to 3.89)	(-6.68 to 4.68)	(-7.50 to 4.61)	
	P	0.44	0.49	0.40		0.17	0.23	0.12		0.28	0.30	0.24		0.40	0.46	0.35		0.54	0.65	0.55	
ASMRC, age-standardized mortality rate by Chinese standard population; ASMRW, age-standardized mortality rate by World Segi’s standard population; AAPC: average annual percentage change

Fig. 2 Time-trends of mortality for the older gastric cancer in the highest gastric cancer risk area in China, 2010 to 2019. A: the mortality of older gastric cancer; B: ASMRC of older gastric cancer; C: ASMRW of older gastric cancer; D:the mortality of male older gastric cancer; E: ASMRC of male older gastric cancer; F: ASMRW of male older gastric cancer; G: the mortality of femal older gastric cancer; H: ASMRC of femal older gastric cancer; I: ASMRW of femal older gastric cancer

Survival of older gastric cancer from 2010 to 2019

Based on the three high-volume gastric cancer cohorts in the highest gastric cancer risk area in China(Supplementary Table 1, Supplementary Tables 2, and Supplementary Table 3), the survival of older gastric cancer patients during 2010–2019 was shown in Table 3; Fig. 3. Overall, the median OS and PFS were observed to be 34.0 and 33.0 months, and the 3-year OS and the 3-year PFS were 46.9%(95%CI: 45.1–48.8%), 45.8%(95%CI: 44.0–47.7%), respectively. Following stratification by pTNM stage, older patients exhibited the 3-year OS of 83.7%, 65.9%, 47.2% and 15.7% for pTNM stages I, II, III, and IV, respectively. Similarly, the 3-year PFS for older patients with pTNM stages I, II, III, and IV were 82.9%, 64.7%, 45.0% and 14.7%, respectively. A higher survival rate was detected in female compared to male patients (the 3-year OS 45.5% (95%CI: 43.4–47.6%) in male, 51.8% (95%CI: 48.0–55.8%) in female, respectively). Moreover, the survival trends of older gastric cancer were observed to decrease during the period of 2010 to 2019 (As shown in Fig. 3). In detail, the 3-year OS decreased from 58.5% in 2010 to 34.4% in 2019, while the 3-year PFS decreased from 51.3% in 2010 to 34.2% in 2019. When the survival trend was stratified by sex, the relative decrease was greater among male than female.

Table 3 A. Survival rates of older gastric cancer patients at different ages in the highest gastric cancer risk area in China, 2010 to 2019. B. Survival rates of older gastric cancer patients at different pathological TNM stage in the highest gastric cancer risk area in China, 2010 to 2019

Age group	Sex	N	OS		PFS	
1-Year, % (95% Cl)	2-Year, %
(95% Cl)	3-Year, %
(95% Cl)	median survival (month)(95%CI)		1-Year, % (95% Cl)	2-Year, %
(95% Cl)	3-Year, %
(95% Cl)	median survival (month)	
A.	
All	Total	3423	80.2(78.7–81.7)	61.0(59.2–62.8)	46.9(45.1–48.8)	34(32–36)		78.7(77.2–80.2)	59.5(57.7–61.4)	45.8(44.0-47.7)	33(31–35)	
	Male	2649	80.5(78.9–82.2)	60.3(58.3–62.4)	45.5(43.4–47.6)	33(31–35)		78.9(77.2–80.7)	58.7(56.7–60.8)	44.3(42.3–46.5)	32(30–34)	
	Female	744	78.9(75.9–82.2)	63.3(59.7–67.1)	51.8(48.0-55.8)	38(33–42)		78.0(74.9–81.3)	62.2(58.6–66.1)	50.7(47.0-54.7)	37(32–40)	
65–69	Total	1526	81.4(79.2–83.6)	63.1(60.5–65.9)	49.3(46.6–52.2)	36(33–39)		79.7(77.5–82.0)	61.7(59.0-64.4)	48.3(45.6–51.2)	35(32–38)	
	Male	1193	82.0(79.6–84.5)	63.1(60.1–66.2)	48.5(45.4–51.8)	35(32–39)		80.1(77.6–82.7)	61.6(58.6–64.7)	47.6(44.6–50.9)	34(31–38)	
	Female	333	79.0(74.3–84.1)	63.3(57.8–69.3)	52.3(46.7–58.7)	38(31–46)		78.2(73.4–83.3)	62.0(56.5–68.1)	51.0(45.4–57.4)	38(30–44)	
70–74	Total	986	79.8(77.1–82.6)	60.2(57.0-63.7)	45.8(42.5–49.4)	33(30–36)		78.6(75.9–81.5)	58.4(55.1–61.8)	44.3(41.0-47.8)	32(29–35)	
	Male	772	80.5(77.5–83.7)	60.6(56.9–64.5)	45.0(41.3–49.1)	33(30–36)		79.2(76.2–82.5)	58.5(54.8–62.4)	43.4(39.7–47.4)	32(28–35)	
	Female	214	77.0(71.2–83.4)	59.0(52.3–66.6)	48.5(41.8–56.4)	35(26–45)		76.5(70.6–82.9)	57.9(51.2–65.5)	47.5(40.7–55.3)	33(26–44)	
75–79	Total	554	77.6(73.8–81.5)	55.8(51.4–60.5)	41.3(37.1–46.1)	28(25–33)		76.0(72.2–80.0)	54.5(50.1–59.2)	40.5(36.2–45.2)	27(25–32)	
	Male	420	77.2(72.9–81.8)	53.2(48.2–58.8)	38.5(33.7–44.0)	26(24–30)		76.0(71.5–80.6)	51.9(46.9–57.5)	37.4(32.6–43.0)	26(23–30)	
	Female	134	78.6(71.5–86.4)	63.2(55.1–72.6)	49.6(41.3–59.5)	36(27–42)		76.3(69.0-84.3)	59.9(53.8–66.7)	45.4(40.9–59.0)	35(27–42)	
80–84	Total	269	80.8(75.8–86.1)	60.7(54.6–67.5)	46.8(40.7–53.8)	33.5(29–39)		78.8(73.6–84.4)	65.0(58.9–71.9)	46.1(39.3–52.5)	32.5(28–38)	
	Male	199	80.2(74.4–86.5)	58.1(51.1–66.1)	43.1(36.2–51.3)	32(25–32)		77.6(71.5–84.2)	57.0(49.9–65.0)	41.8(34.9–50.0)	31(24–37)	
	Female	70	82.5(73.2–92.9)	68.4(57.4–81.6)	57.8(46.3–72.2)	40(28–51)		82.5(73.2–92.9)	68.4(57.4–81.6)	56.1(44.6–70.6)	39(28–51)	
≥ 85	Total	88	79.5(70.7–89.3)	67.1(57.2–78.8)	54.7(44.4–67.4)	38(31–49)		79.5(70.7–89.3)	67.1(57.2–78.8)	54.7(44.4–67.4)	38(31–49)	
	Male	65	76.5(65.7–89.0)	58.8(46.8–74.0)	49.0(37.1–64.9)	36(21–45)		76.5(65.7–89.0)	58.8(46.8–74.0)	49.0(37.1–64.9)	36(21–45)	
	Female	23	86.4(73.2–100.0)	86.4(73.2–100.0)	67.9(50.8–90.7)	50(42–69)		86.4(73.2–100.0)	86.4(73.2–100.0)	67.9(50.8–90.7)	50(42–69)	
B.	
pTNM I	Total	321	95.5(92.8–98.3)	89.6(85.7–93.7)	83.7(78.9–88.7)	104(-)		95.1(92.3–98.0)	89.2(85.3–93.4)	82.9(78.0–88.0)	104(-)	
	Male	239	95.7(92.6–98.9)	88.3(83.6–93.4)	80.2(74.3–86.6)	103(-)		95.1(91.9–98.5)	87.8(82.9–93.0)	79.1(73.1–85.6)	103(-)	
	Female	82	94.9(89.5–100.0)	93.2(87.0-99.9)	93.2(87.0-99.9)	105(-)		94.9(89.5–100.0)	93.2(87.0-99.9)	93.2(87.0-99.9)	104(-)	
pTNM II	Total	334	88.1(84.1–92.4)	79.2(74.2–84.6)	65.9(60.1–72.3)	60(52–84)		86.9(82.7–91.3)	78.4(73.3–83.8)	64.7(58.8–71.1)	59(49–84)	
	Male	258	86.4(81.5–91.6)	75.1(69.0-81.8)	62.0(55.2–69.6)	54(44–63)		84.7(79.6–90.2)	74.0(67.8–80.8)	60.9(54.1–68.5)	52(42–63)	
	Female	76	93.2(87.0-99.9)	91.5(84.7–98.9)	77.7(67.7–89.2)	88(-)		93.2(87.0-99.9)	91.5(84.7–98.9)	76.0(65.8–87.8)	88(-)	
pTNM III	Total	746	85.9(83.2–88.7)	63.5(59.8–67.5)	47.2(43.4–51.3)	35(31–37)		84.0(81.1–86.9)	60.9(57.2–64.9)	45.0(41.2–49.2)	32(29–36)	
	Male	599	86.0(83.1–89.0)	63.2(59.0-67.6)	46.2(42.0-50.9)	34(35–42)		84.2(81.0-87.5)	60.6(56.4–65.1)	44.3(40.1–48.9)	32(28–36)	
	Female	147	85.4(79.3–91.8)	65.0(57.1–74.0)	51.0(42.9–60.7)	37(30–37)		83.2(76.9–90.0)	62.4(54.5–71.5)	47.9(39.9–57.6)	33(27–42)	
pTNM IV	Total	128	50.9(42.3–61.3)	25.9(18.8–35.7)	15.7(10.2–24.4)	13(9–16)		48.6(40.1–59.0)	23.9(17.1–33.4)	14.7(9.3–23.1)	32(29–36)	
	Male	101	48.8(39.2–60.8)	25.0(17.3–36.2)	13.1(7.6–22.7)	12(9–17)		45.9(36.4–57.8)	22.4(15.0-33.2)	11.8(6.6–21.1)	11(9–16)	
	Female	27	58.3(41.6–81.8)	29.2(15.6–54.4)	25.0(12.5–50.0)	14(8–31)		58.3(41.6–81.8)	29.2(15.6–54.4)	25.0(12.5–50.0)	14(8–31)	

Fig. 3 Time-trends of survival for the older gastric cancer cases in the highest gastric cancer risk area in China, 2010 to 2019. A: Overall survival; B: Progression-free survival

ARIMA models of older gastric cancer from 2020 to 2024

The ARIMA models of future trends in older gastric cancer incidence and mortality through 2024 in the highest gastric cancer risk area in China were presented in Fig. 4. According to this graph, it could be observed that the projected incidence and mortality were expected to exhibit a continued decline between 2020 and 2024. The incidence rate of older gastric cancer in 2024 were expected to decrease to 205.59 per 100,000 (MES: 31.55), and the mortality rate in 2024 were expected to decrease to 186.22 per 100,000 (MES: 39.87).

Fig. 4 ARIMA models for the older gastric cancer in the highest gastric cancer risk area in China, 2020 to 2024. A: Projection of incidence; B: Projections of mortality

Discussion

Gansu Province was located in the northwest of China and had a population of 24.65 million in 2023. In recent years, Gansu Province has experienced an increase in the aging population, with an increase from 8.23% in 2010 to 13.65% in 2023. Gastric cancer ranks first in incidence rate and mortality rate among all malignancies in Gansu province [7]. Gansu Central Cancer Registry was first established in 2005 to monitor the cancer burden and provide a decision-making basis for cancer control and prevention policies [12]. There are currently 23 cancer registries establised in Gansu Province covering 86 counties and districts, accounting for about 36.96% of the total population, which might accurately reflect cancer incidence and mortality for the whole province [13].

This study presented a comprehensive analysis of time-trends in the incidence, mortality, and survival of older gastric cancer in Gansu province from 2010 to 2019, and forecast gastric cancer burden of older individuals through 2024. Several key observations could be derived from our study. First, the trends of incidence and mortality of older gastric cancer remained stable from 2010 to 2019, while the survival exhibited a decline. Second, the incidence and mortality of older gastric cancer in Gansu province were projected to decrease to 205.59 per 100,000 (95%CI: 175.3 per 100000 to 235.88 per 100000) and 186.22 per 100,000 (95%CI: 106.93 per 100000 to 265.51 per 100000) by 2024.

In 2019, the ASIRW and ASMRW of gastric cancer among older individuals in Gansu province was 334.38 per 100,000 and 326.27 per 100,000, which was lower than the corresponding rates of 422.18 per 100,000 for ASIRW and 330.17 per 100,000 for ASMRW in 2010. Generally, it was widely thought that the decline in incidence and mortality attributable to the decrease in risk factors for gastric cancer. Helicobacter pylori (Hp) infection has been proven to play an important role in gastric carcinogenesis [14, 15]. Intervention study indicated that the eradication of Hp has been shown to reduce the risk of early gastric cancer by nearly 50% [16]. Thus, the decline in Hp prevalence in Gansu province in recent decades might resulted in the decreasing of gastric cancer incidence among older individuals [17]. Furthermore, environmental factors such as diet, smoking, diabetes, and metabolism diseases also play significant roles in gastric cancer development [18–21]. Recently, the promotion of healthy lifestyles including a balanced diet, low salt diet, smoking cessation and alcohol restriction in Gansu province might led to the decline of incidence and mortality of older gastric cancer [22].

From 2010 to 2019, the present study revealed the decreased survival rates among older gastric cancer patients in Gansu province, with the reduction of 24.1% in the 3-year overall survival rates and the decrease of 11.0 months in median survival. In general, the decline in survival rates among older patients in Gansu province might be partially attributed to the rise of average diagnosis age, which increased from 69 in 2010 to 72 in 2019. Multiple studies suggested that advanced age was associated with a poor prognosis in gastric cancer [23–28]. This correlation might be attributed to the reduced organ function, pharmacokinetic and pharmacodynamic variability, as well as the presence of severe comorbidities in older patients [28]. Moreover, our findings showed that there has been a rise in the percentage of older gastric cancer with pTNM stage IV, which increased from 8.33% in 2010 to 13.15% in 2019. As for the pathological TNM II/III, there was a decline from 27.78 to 20.28%, from 52.78 to 44.87%, respectively. In addition, the percentage of perioperative chemotherapy in older patients with local advanced gastric cancer decreased from 73.68% in 2010 to 52.77% in 2019, which might play a role in the survival decline of older patients in Gansu province.

Significantly higher incidence and mortality rates of older gastric cancer were observed in males compared to females in Gansu province. The reason for this discrepancy was not immediately clear. Several studies found that estrogen was associated with lowered risk of gastric cancer incidence and mortality among women [29, 30]. Larsson et al. [31] showed that the risk factors of gastric cancer, like Hp infection or alcohol drinking, were more prevalent in males than females. Furthermore, our study revealed a notable disparity in the prevalence of gastric cancer among older individuals in the urban and rural areas, potentially attributable to the comparatively limited economic status, inadequate healthcare facilities, and deficient public health consciousness prevalent in rural areas. The highlighted health disparities emphasize the urgency of establishing effective referral channels and developing user-friendly treatment technologies in low-health resource areas to enhance healthcare accessibility and efficacy.

One of the main strengths of this study was the combination of registration data and hospital-based data, enabling the systematic exploration of the incidence, mortality, and survival rates of older gastric cancer in the highest gastric cancer risk area in China. Another strength was that we firstly established the cancer burden model for older gastric cancer, which potentially offering valuable insights for regional gastric cancer prevention and treatment. However, when interpreting the findings of this study, several potential limitations needed to be considered. Firstly, the incidence and mortality data were estimated from cancer registration, which covered 36.96% of the total population in Gansu Province. Nevertheless, at this level of coverage, population-based cancer registration was thought to be able to provide scientific information for developing cancer control policies [12]. Secondly, some variables including the anatomical site, and cause specific survival were not included in our analysis, which might limit our ability to conduct further analyses.

Conclusion

From 2010 to 2019, the incidence and mortality of older gastric cancer remained stable, while the survival rates showed decline in the highest gastric cancer risk area in China. Moreover, the ARIMA models showed the sustained decline in the incidence and mortality of gastric cancer among older individuals over the next five years. More measures and strategies were expected to be proposed for the prevention, early diagnosis, and treatment improvement of older gastric cancer in the highest gastric cancer risk area in China.

Contributors

The conception and design: Penghui Niu, Mingyan He, Quanlin Guan, Dongbing Zhao, Yingtai Chen, Yumin Li, Yuqin Liu; Study material or patients: Fan Zhang, Deyuan Ma, Xiadong Zhou, Yitong Zhu, Lulu Zhao, Xiaoyi Luan, Wanqing Wang; Collecting and/or assembling data: Xiaojie Zhang, Xiaoyi Luan, Xue Han; Data analysis and interpretation: Penghui Niu, Lulu Zhao; Writing: Penghui Niu, Lulu Zhao, Deyuan Ma, Xiadong Zhou.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Acknowledgements

All authors made substantial contributions to the intellectual content of this paper.

Author contributions

The conception and design: Penghui Niu, Mingyan He, Quanlin Guan, Dongbing Zhao, Yingtai Chen, Yumin Li, Yuqin Liu; Study material or patients: Fan Zhang, Deyuan Ma, Xiadong Zhou, Yitong Zhu, Lulu Zhao, Xiaoyi Luan, Wanqing Wang; Collecting and/or assembling data: Xiaojie Zhang, Xiaoyi Luan, Xue Han; Data analysis and interpretation: Penghui Niu, Lulu Zhao; Writing: Penghui Niu, Lulu Zhao, Deyuan Ma, Xiadong Zhou.

Funding

This study was supported by Beijing Hope Run Special Fund of Cancer Foundation of China (Grant No. LC2022A29), 2023 Scientific Research Project of Chronic Diseases Control and Health Education (No.BJMB0012023024005), and Beijing Nova Program (No.20220484200).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethical approval

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was approved by the ethics committee of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (No. 17–156/1412). Informed consent was obtained from all subjects and/or their legal guardian(s).

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Penghui Niu, Fan Zhang, Deyuan Ma, Xiadong Zhou, Yitong Zhu, Xiaoyi Luan, Lulu Zhao and Wanqing Wang contributed equally to this work.
==== Refs
References

1. Fane M Weeraratna AT How the ageing microenvironment influences tumour progression Nat Rev Cancer 2020 20 2 89 106 10.1038/s41568-019-0222-9 31836838
Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89–106.31836838 10.1038/s41568-019-0222-9
2. Pilleron S Sarfati D Janssen-Heijnen M Vignat J Ferlay J Bray F Global cancer incidence in older adults, 2012 and 2035: a population-based study Int J Cancer 2019 144 1 49 58 10.1002/ijc.31664 29978474
Pilleron S, Sarfati D, Janssen-Heijnen M, Vignat J, Ferlay J, Bray F, et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144(1):49–58.29978474 10.1002/ijc.31664
3. Anderson WF Camargo MC Fraumeni JF Jr Correa P Rosenberg PS Rabkin CS Age-specific trends in incidence of noncardia gastric cancer in US adults JAMA 2010 303 17 1723 8 10.1001/jama.2010.496 20442388
Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, Rabkin CS. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA. 2010;303(17):1723–8.20442388 10.1001/jama.2010.496
4. Zeng H Chen W Zheng R Zhang S Ji JS Zou X Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries Lancet Glob Health 2018 6 5 e555 67 10.1016/S2214-109X(18)30127-X 29653628
Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555–67.29653628 10.1016/S2214-109X(18)30127-X
5. He J, Wei W, CHINA CANCER REGISTRY ANNUAL, REPORT. 2019. Beijing: People’s Medical Publishing House.
6. Wang J Wang Y Cai H Zhang J Pan B Bao G Analysis of the status quo of the Elderly’s demands of medical and elderly care combination in the underdeveloped regions of Western China and its influencing factors: a case study of Lanzhou BMC Geriatr 2020 20 1 338 10.1186/s12877-020-01616-6 32907557
Wang J, Wang Y, Cai H, Zhang J, Pan B, Bao G, et al. Analysis of the status quo of the Elderly’s demands of medical and elderly care combination in the underdeveloped regions of Western China and its influencing factors: a case study of Lanzhou. BMC Geriatr. 2020;20(1):338.32907557 10.1186/s12877-020-01616-6
7. Li CY Ye YC Liang GY Zhang WH Zhang ZY Liu XQ Cancer Incidence and Mortality Survey in Wuwei, Gansu Province, Northwestern China from 2003 to 2012: a Retrospective Population-based study Chin Med J (Engl) 2016 129 6 636 44 10.4103/0366-6999.177969 26960365
Li CY, Ye YC, Liang GY, Zhang WH, Zhang ZY, Liu XQ, et al. Cancer Incidence and Mortality Survey in Wuwei, Gansu Province, Northwestern China from 2003 to 2012: a Retrospective Population-based study. Chin Med J (Engl). 2016;129(6):636–44.26960365 10.4103/0366-6999.177969
8. National Cancer Center.Chinese guideline for cancer regis tration. (2016). Beijing:People’s Medical Publishing House (In Chinese), 2016.59-75.
9. Bray F Parkin DM Evaluation of data quality in the cancer registry: principle and methods. Part I: comparability, validity and timeliness Eur J Cancer 2009 45 5 747 55 10.1016/j.ejca.2008.11.032 19117750
Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principle and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009;45(5):747–55.19117750 10.1016/j.ejca.2008.11.032
10. Parkin DM Bary F Evaluation of data quality in the cancer registry: principle and methods. Part II: comparability, validity and timeliness Eur J Cancer 2009 45 5 756 64 10.1016/j.ejca.2008.11.033 19128954
Parkin DM, Bary F. Evaluation of data quality in the cancer registry: principle and methods. Part II: comparability, validity and timeliness. Eur J Cancer. 2009;45(5):756–64.19128954 10.1016/j.ejca.2008.11.033
11. Felay J. The IARCcrgTools program[EB/OL]. http://www.iacr.com.fr/index. php?option = com_content&view = category&layout = blog&id = 68&Itemid = 445, 2017-10-1.
12. Bray F Znaor A Cueva P Planning and developing Population-Based Cancer Registration in Low- or middle-income settings 2014 Lyon (FR) International Agency for Research on Cancer
Bray F, Znaor A, Cueva P, et al. Planning and developing Population-Based Cancer Registration in Low- or middle-income settings. Lyon (FR): International Agency for Research on Cancer; 2014.
13. Arnold M Abnet CC Neale RE Vignat J Giovannucci EL McGlynn KA Global burden of 5 major types of gastrointestinal Cancer Gastroenterology 2020 159 1 335 e34915 10.1053/j.gastro.2020.02.068 32247694
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal Cancer. Gastroenterology. 2020;159(1):335–e34915.32247694 10.1053/j.gastro.2020.02.068
14. Collatuzzo G Pelucchi C Negri E López-Carrillo L Tsugane S Hidaka A Exploring the interactions between Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: a pooled analysis in the stomach cancer pooling (StoP) project Int J Cancer 2021 149 6 1228 38 10.1002/ijc.33678 33990950
Collatuzzo G, Pelucchi C, Negri E, López-Carrillo L, Tsugane S, Hidaka A, et al. Exploring the interactions between Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: a pooled analysis in the stomach cancer pooling (StoP) project. Int J Cancer. 2021;149(6):1228–38.33990950 10.1002/ijc.33678
15. He J Hu W Ouyang Q Zhang S He L Chen W Helicobacter pylori infection induces stem cell-like properties in Correa cascade of gastric cancer Cancer Lett 2022 542 215764 10.1016/j.canlet.2022.215764 35654291
He J, Hu W, Ouyang Q, Zhang S, He L, Chen W, et al. Helicobacter pylori infection induces stem cell-like properties in Correa cascade of gastric cancer. Cancer Lett. 2022;542:215764.35654291 10.1016/j.canlet.2022.215764
16. den Hoed CM Kuipers EJ Gastric Cancer: how can we reduce the incidence of this disease? Curr Gastroenterol Rep 2016 18 7 34 10.1007/s11894-016-0506-0 27184043
den Hoed CM, Kuipers EJ. Gastric Cancer: how can we reduce the incidence of this disease? Curr Gastroenterol Rep. 2016;18(7):34.27184043 10.1007/s11894-016-0506-0
17. Meng W Bai B Sheng L Li Y Yue P Li X Role of Helicobacter pylori in gastric cancer: advances and controversies Discov Med 2015 20 111 285 93 26645900
Meng W, Bai B, Sheng L, Li Y, Yue P, Li X, et al. Role of Helicobacter pylori in gastric cancer: advances and controversies. Discov Med. 2015;20(111):285–93.26645900
18. Smyth EC Nilsson M Grabsch HI van Grieken NC Lordick F Gastric cancer Lancet 2020 396 635 48 10.1016/S0140-6736(20)31288-5 32861308
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48.32861308 10.1016/S0140-6736(20)31288-5
19. Buckland G Travier N Huerta JM Bueno-de-Mesquita HB Siersema PD Skeie G Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study Int J Cancer 2015 137 598 606 10.1002/ijc.29411 25557932
Buckland G, Travier N, Huerta JM, Bueno-de-Mesquita HB, Siersema PD, Skeie G, et al. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer. 2015;137:598–606.25557932 10.1002/ijc.29411
20. https://www.gansu.gov.cn/gsszf/c100055/201612/100677.shtml
21. Zhu C Ma H He A Li Y He C Xia Y Exercise in cancer prevention and anticancer therapy: efficacy, molecular mechanisms and clinical information Cancer Lett 2022 544 215814 10.1016/j.canlet.2022.215814 35803475
Zhu C, Ma H, He A, Li Y, He C, Xia Y. Exercise in cancer prevention and anticancer therapy: efficacy, molecular mechanisms and clinical information. Cancer Lett. 2022;544:215814.35803475 10.1016/j.canlet.2022.215814
22. Malik S Stokes Iii J Manne U Singh R Mishra MK Understanding the significance of biological clock and its impact on cancer incidence Cancer Lett 2022 527 80 94 10.1016/j.canlet.2021.12.006 34906624
Malik S, Stokes Iii J, Manne U, Singh R, Mishra MK. Understanding the significance of biological clock and its impact on cancer incidence. Cancer Lett. 2022;527:80–94.34906624 10.1016/j.canlet.2021.12.006
23. Konishi H Ichikawa D Itoh H Fukuda K Kakihara N Takemura M Surgery for gastric cancer patients of age 85 and older: Multicenter survey World J Gastroenterol 2017 23 7 1215 23 10.3748/wjg.v23.i7.1215 28275301
Konishi H, Ichikawa D, Itoh H, Fukuda K, Kakihara N, Takemura M, et al. Surgery for gastric cancer patients of age 85 and older: Multicenter survey. World J Gastroenterol. 2017;23(7):1215–23. 10.3748/wjg.v23.i7.1215.28275301 10.3748/wjg.v23.i7.1215
24. Han C Zhan Q Precision medicine revolutionizes cancer diagnosis and treatment Med Revi 2022 2 6 541 3 10.1515/mr-2022-0041
Han C, Zhan Q. Precision medicine revolutionizes cancer diagnosis and treatment. Med Revi. 2022;2(6):541–3.10.1515/mr-2022-0041
25. Liu L Chen J Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives Med Revi 2022 2 6 555 69 10.1515/mr-2022-0033
Liu L, Chen J. Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. Med Revi. 2022;2(6):555–69.10.1515/mr-2022-0033
26. Zhang X He C Xiang G Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy Cancer Lett 2022 530 110 27 10.1016/j.canlet.2022.01.012 35041892
Zhang X, He C, Xiang G. Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy. Cancer Lett. 2022;530:110–27.35041892 10.1016/j.canlet.2022.01.012
27. An J Ma X Zhang C Zhou W Wang C Miao W Comparison of incidence and prognosis between young and old gastric cancer patient in North-Western China: a retrospective cohort study Med (Baltim) 2022 101 42 e31255 10.1097/MD.0000000000031255
An J, Ma X, Zhang C, Zhou W, Wang C, Miao W, et al. Comparison of incidence and prognosis between young and old gastric cancer patient in North-Western China: a retrospective cohort study. Med (Baltim). 2022;101(42):e31255.10.1097/MD.0000000000031255
28. Joharatnam-Hogan N Shiu KK Khan K Challenges in the treatment of gastric cancer in the older patient Cancer Treat Rev 2020 85 101980 10.1016/j.ctrv.2020.101980 32065879
Joharatnam-Hogan N, Shiu KK, Khan K. Challenges in the treatment of gastric cancer in the older patient. Cancer Treat Rev. 2020;85:101980.32065879 10.1016/j.ctrv.2020.101980
29. Tang W Liu R Yan Y Pan X Wang M Han X Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer Oncotarget 2017 8 25 40765 77 10.18632/oncotarget.16582 28388558
Tang W, Liu R, Yan Y, Pan X, Wang M, Han X, et al. Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer. Oncotarget. 2017;8(25):40765–77.28388558 10.18632/oncotarget.16582
30. Karimi P Islami F Anandasabapathy S Freedman ND Kamangar F Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention Cancer Epidemiol Biomarkers Prev 2014 23 5 700 13 10.1158/1055-9965.EPI-13-1057 24618998
Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–13.24618998 10.1158/1055-9965.EPI-13-1057
31. Larsson SC Carter P Kar S Vithayathil M Mason AM Michaëlsson K Smoking, alcohol consumption, and cancer: a mendelian randomisation study in UK Biobank and international genetic consortia participants PLoS Med 2020 17 7 e1003178 10.1371/journal.pmed.1003178 32701947
Larsson SC, Carter P, Kar S, Vithayathil M, Mason AM, Michaëlsson K, et al. Smoking, alcohol consumption, and cancer: a mendelian randomisation study in UK Biobank and international genetic consortia participants. PLoS Med. 2020;17(7):e1003178. Published 2020 Jul 23.32701947 10.1371/journal.pmed.1003178
